Navigation Links
Pharmos Corporation Reports 2008 Third Quarter Results
Date:11/6/2008

result from non recurring 2007 costs related to contractual payment obligations associated with the retirement of the Company's chief executive officer, higher legal and accounting fees in 2007, a one time IRS section 382 tax analysis cost incurred in 2007, a non recurring recruitment fee of $42,000 in 2007 and higher BOD meeting costs in 2007.

The company believes that the current cash and cash equivalents totaling $6.1 million as of September 30, 2008 will be sufficient to support the currently planned continuing operations through at least December 31, 2008. The company is actively pursuing efforts to raise additional capital but there can be no assurance that such efforts will be successful.

About Pharmos Corporation

Pharmos discovers and develops novel therapeutics to treat a range of indications including specific diseases of the nervous system such as disorders of the brain-gut axis (GI/IBS), pain/inflammation, and autoimmune disorders. The Company's lead product in development, dextofisopam, is undergoing Phase 2b testing in IBS patients. Dextofisopam has completed a Phase 2a IBS study in which it demonstrated a statistically significant effect compared to placebo on the primary efficacy endpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and other disorders. Pharmos is also working to commercialize its proprietary NanoEmulsion drug delivery system, which is in clinical-stage development for topical application of analgesic and anti-inflammatory agents.

Safe Harbor Statement

Statements made in this press release related to the business outlook and future financial performance of Phar
'/>"/>

SOURCE Pharmos Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Pharmos Restructures Operations in Israel
2. Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
3. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
4. Brooke Franchise Corporation Announces Selected July Results
5. MedThink Communications Retained by NanoBio Corporation
6. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
7. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
8. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
9. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
10. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
11. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... Coast Dental Vista is celebrating its ... a.m. to 3 p.m. near Albertsons in the Foothill Center, located at 1279 E. ... Rivera and Dr. Jay Lopp. Call (760) 208-2518 for more details or stop by ...
(Date:8/31/2015)... ... August 31, 2015 , ... Garden State Urology is ... result of a merger of five of the busiest urology practices in Morris ... more cost-effective and higher quality care than they did individually. Their mission ...
(Date:8/31/2015)... ... August 31, 2015 , ... With the FCPX LUT Soft pack from Pixel Film ... a Lookup Table that contains a mathematical formula for modifying an image. The LUT changes ... 60 soft CUBE LUT files. , FCPX LUT Soft requires Final Cut Pro X ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... ABBY Awards, at the 16th Innovations in Healthcare(SM) Awards Event , on ... Business Leaders (ABL) Organization , recognizes innovative organizations and individuals who are dramatically ...
(Date:8/31/2015)... ... August 31, 2015 , ... Finnleo , a leader ... Available starting in the 3rd quarter, the newly re-styled and re-designed “Hallmark Series” updates ... tools. , These new models include more glass and a more upscale feel than ...
Breaking Medicine News(10 mins):Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 3Health News:NJ Top Docs Presents, Garden State Urology! 2Health News:Pixel Film Studios, FCPX Plugin Developer, Releases FCPX LUT Soft 2Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 2Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 4Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 5Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 6Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 7Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 8Health News:Finnleo Introduces Hallmark Series Saunas 2
... 11 (HealthDay News) -- Low oxygen supply (hypoxia) increases the ... a severe traumatic brain injury (TBI), a new study finds. ... with TBI, most of whom had bleeding within the brain ... fared poorly, suffering severe disability, dying or being in a ...
... SAN FRANCISCO, CA NOVEMBER 11, 2011 ... demonstrated that cryoplasty post-dilitation compared to conventional balloon ... the risk of in-stent restenosis (ISR). Results from ... the 23rd Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific ...
... FRIDAY, Nov. 11 (HealthDay News) -- Repeated bouts of ... pain and infertility, a new study says. Pelvic inflammatory ... is marked by inflammation of the reproductive organs. The condition ... year and one in 10 of them becomes infertile, according ...
... SAN FRANCISCO, CA NOVEMBER 11, 2011 ... de novo coronary artery lesions showed a significantly ... to paclitaxel-eluting stents with permanent polymers. ... at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) ...
... the past 100 years, the Haber-Bosch process has been used ... the manufacture of fertilizer. Despite the longstanding reliability of the ... works. But now a team of chemists, led by Patrick ... how the ammonia is formed. Their findings are published in ...
... FRIDAY, Nov. 11 (HealthDay News) -- Age-related declines in ... to a new study. "The more income and ... be," co-author Virginia Richardson, a professor of social work ... release. The researchers analyzed data from roughly 6,500 ...
Cached Medicine News:Health News:Results of the COBRA trial reported at TCT 2011 2Health News:STD Complication May Double Infertility Risk 2Health News:Results of the NEXT clinical trial Reported at TCT 2011 2Health News:Researchers gain insight into 100-year-old Haber-Bbosch process 2
(Date:8/31/2015)... Mich. , Aug. 31, 2015  Diplomat Pharmacy, Inc. ... has announced that Phil Hagerman , Chairman & CEO, ... upcoming investor conferences. Mr. Hagerman and Mr. ... Healthcare Conference in Boston on Wednesday, ... Hagerman and Mr. Whelan are also scheduled to participate in ...
(Date:8/31/2015)... , Aug. 31, 2015  Qualcomm Incorporated ... subsidiary, Qualcomm Life, Inc., is collaborating ... chronic care management solutions powered by Qualcomm Life,s ... Platform to enable continuous care, informed interventions and ... announced at Qualcomm Life,s annual Connect 2015 ...
(Date:8/31/2015)... , Aug. 31, 2015  Asterias Biotherapeutics, ... on the emerging field of regenerative medicine, today ... at Chicago -based Rush University ... evaluating activity of escalating doses of AST-OPC1 (oligodendrocyte ... and motor complete cervical spinal cord injury (SCI). ...
Breaking Medicine Technology:Diplomat to Participate in Upcoming Investor Conferences 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6
... /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... medical devices worldwide, announced today that it will attend ... Fuzhou, China between October 31 and November 3, 2011. ... products from its three primary business segments: patient monitoring ...
... SINGAPORE, Oct. 25, 2011 S*BIO Pte Ltd today announced ... its novel JAK2 inhibitor pacritinib (SB1518), in the first half ... the treatment of myelofibrosis (MF). The company is actively exploring ... "Data from Phase 1 and 2 clinical ...
Cached Medicine Technology:Mindray Medical to Exhibit New Products at 66th China International Medical Equipment Fair 2Mindray Medical to Exhibit New Products at 66th China International Medical Equipment Fair 3S*BIO to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF) 2
... technology enables a fast, precise patternless edge ... Introducing the TOPCON ALE-X1. The latest advance ... of improved features and functions. High-speed processing, ... and beveled edges, precise three-dimensional frame tracing ...
Inquire...
Inquire...
A professionally designed instrument for obtaining accurate measurements of the corneal curvature. The convenient configuration also facilitates measuring contact lens curvatures....
Medicine Products: